Intuitive Surgical Inc

Intuitive Surgical Inc(ISRG)股票分析

$444.180

-1.688 (-0.38%)收盤時

Loading chart…
最高
449.970
開盤
441.425
成交量加權均價
443.89
成交量
1.85M
市值
157.88B
最低
437.510
成交金額
819.02M
企業價值/稅息折舊攤銷前利潤(TTM)
29.13

Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.

AI 分析 of Intuitive Surgical Inc (ISRG)

買進

Intuitive Surgical Inc is a good buy right now due to its recent earnings beat with an EPS of $2.53, exceeding estimates by 18.78%, and a forward P/E ratio of 33.33, indicating growth potential at a reasonable valuation. The stock has shown a positive momentum with a 5-day change of +6.00% and a current RSI of 76.78, suggesting strong buying interest. However, the main risk is the recent 10% drop in share price following disappointing earnings, which could indicate market volatility ahead.

分析師評級(17)

上檔空間 +43.48%
買進
11 買進
5 持有
1 賣出
目前: 444.18
最低
575.00
平均
637.32
最高
740.00

BTIG

2026-10-12

目標價

$454

買進

Barclays

2026-10-06

目標價

$485

增持

Oppenheimer

2026-08-12

目標價

—

優於大盤

HSBC

2026-07-30

目標價

$391

持有

UBS

2026-07-28

目標價

$500

買進

估值指標

Intuitive Surgical Inc(ISRG)目前預期本益比為 37.17,5 年平均預期本益比為 53.89。

預期本益比

低估
5 年均值 P/E
53.89
目前P/E
37.17
高估
64.59
低估
43.19

預期 EV/EBITDA

低估
5 年均值 EV/EBITDA
37.00
目前EV/EBITDA
29.13
高估
44.26
低估
29.74

預期股價營收比

低估
5 年均值 P/S
15.37
目前P/S
11.81
高估
18.67
低估
12.07

Alphio AI 對 ISRG 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%ISRG

$605.58

情境價格

基

基準

基準 · 50%ISRG

$559.78

情境價格

悲

悲觀

悲觀 · 25%ISRG

$542.00

情境價格

持有 ISRG 的大戶

L

Lingotto Investment Management LLP

+ 持有ISRG

+24.02%

3個月報酬率

H

Hyperion Asset Management Limited

+ 持有ISRG

+9.63%

3個月報酬率

C

Campbell & Company, LP

+ 持有ISRG

+8.87%

3個月報酬率

M

Millennium Management LLC

+ 持有ISRG

+8.04%

3個月報酬率

E

Entropy Technologies, LP

+ 持有ISRG

+7.73%

3個月報酬率

N

Nan Shan Life Insurance Co., Ltd.

+ 持有ISRG

+7.42%

3個月報酬率

事件時間軸

2026-10-21 (ET)

09:00:00

Stock Futures Rise as Brent Crude Surpasses $110

2026-10-20 (ET)

20:00:00

Treasury Yields Retreat as Netflix Falls Over 5%

17:30:00

Company Sees Continued Segmentation in Q3 Customer Base

17:00:00

da Vinci Surgical Robot Reaches $450M Settlement

16:30:00

Q3 Revenue Reaches $3.05B, Exceeding Consensus

資訊

ISRG 常見問題 —— 由 Alphio AI 解答

Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

Intuitive Surgical Inc is a good buy right now due to its recent earnings beat with an EPS of $2.53, exceeding estimates by 18.78%, and a forward P/E ratio of 33.33, indicating growth potential at a reasonable valuation. The stock has shown a positive momentum with a 5-day change of +6.00% and a current RSI of 76.78, suggesting strong buying interest. However, the main risk is the recent 10% drop in share price following disappointing earnings, which could indicate market volatility ahead.

17 analysts cover ISRG: 11 rate it Buy, 5 Hold and 1 Sell. The average price target is 637.32.

ShortOutpost2026/10/21

$ISRG "Trade Idea 2: Buy the October 23 Expiry 437.50/452.50 Call Spread ($6.60) and sell the October 23 Expiry 410 Put for 30 cents." The call spread looks to be a bust; may need to roll puts down and out.

展開
註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易